Patient Views and Correlates of Radiotherapy Omission in a Population-Based Sample of Older Women with Favorable Prognosis Breast Cancer

Dean Shumway, MD¹; Kent A. Griffith, MPH, MS²; Sarah T. Hawley, PhD, MPH³; Lauren P. Wallner, PhD, MPH⁴; Kevin C. Ward, PhD, MPH⁵; Ann S. Hamilton, PhD⁶; Monica Morrow, MD⁷; Steven Katz, MD, MPH⁸; and Reshma Jagsi, MD, DPhil¹

¹Department of Radiation Oncology, University of Michigan, Ann Arbor, MI

²Center for Cancer Biostatistics, University of Michigan, Ann Arbor

³Departments of Internal Medicine and Health Management and Policy, University of Michigan and Center for Clinical Management Research, Ann Arbor VA Health Care System, Ann Arbor, MI

⁴Departments of Internal Medicine and Epidemiology, University of Michigan, Ann Arbor, MI ⁵Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA

⁶Department of Epidemiology, Emory University, Atlanta, GA

⁷Memorial Sloan-Kettering Cancer Center, New York, NY

⁸Departments of Internal Medicine and Health Management and Policy, University of Michigan, Ann Arbor, MI

Conflicts of Interest:

Dr. Jagsi reports grants from the NIH (R01) during the conduct of the study, grants from the Doris Duke Foundation, and grants from the Greenwall Foundation, outside the submitted work. Other authors have no conflicts of interest to disclose.

Funding: This work was funded by grant P01 CA163233 to the University of Michigan from the National Cancer Institute. The collection of Los Angeles County cancer incidence data used in this study was supported by the California Department of Public Health pursuant to California Health and Safety Code Section 103885; Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries, under cooperative agreement 5NU58DP003862-04/DP003862; the National Cancer Institute's Surveillance, Epidemiology and End Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute. Cancer incidence data collection in Georgia was supported by contract HHSN261201300015I, Task Order HHSN26100006 from the NCI and cooperative agreement 5NU58DP003875-04-00 from the CDC. DS acknowledges support from the National Institutes of Health Claude Pepper Center (AG024824).

Acknowledgments: We acknowledge the work of our project staff (Mackenzie Crawford, M.P.H. and Kiyana Perrino, M.P.H. from the Georgia Cancer Registry; Jennifer Zelaya, Pamela Lee, Maria Gaeta, Virginia Parker, B.A. and Renee Bickerstaff-Magee from USC; Rebecca Morrison, M.P.H., Alexandra Jeanpierre, M.P.H., Stefanie Goodell, B.S., Irina Bondarenko, M.S., Paul Abrahamse, M.A., and Rose Juhasz, Ph.D. from the University of Michigan).

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of record. Please cite this article as doi:10.1002/cncr.31378.

Author Contributions:

Dean Shumway: conceptualization, methodology, investigation, visualization, writing-original draft, writing-review and editing. **Kent A. Griffith:** methodology, data curation, formal analysis, software, writing-original draft, writing-review and editing, and visualization. **Sarah T. Hawley:** conceptualization, methodology, investigation, writing-original draft, writing-review and editing, project administration, and funding acquisition. **Lauren P. Wallner:** conceptualization, methodology, investigation, writing-original draft and writing-review and editing. **Kevin C. Ward:** conceptualization, methodology, investigation, writing-original draft, writing-review and editing, and project administration. **Ann S. Hamilton:** conceptualization, methodology, investigation, writing-review and editing, and project administration, methodology, investigation, writing-review and editing, and project administration. **Monica Morrow:** conceptualization, methodology, investigation, writing-review and editing. **Steven Katz:** conceptualization, methodology, investigation, writing-review and editing, project administration, writing-review and editing, project administration, writing-review and editing, project administration, writing-original draft, writing-review and editing, investigation, writing-original draft, writing-review and editing, investigation, writing-original draft and writing-review and editing. **Steven Katz:** conceptualization, methodology, investigation, writing-original draft, writing-review and editing, project administration, and funding acquisition. **Reshma Jagsi:** conceptualization, methodology, investigation, visualization, writing-original draft, writing-review and editing, and funding acquisition.

Corresponding author: Reshma Jagsi, MD, DPhil Department of Radiation Oncology University of Michigan UHB2C490, SPC 5010 1500 E. Medical Center Drive

Running head: Patient views on radiation omission

Keywords: breast cancer, radiotherapy omission, risk perception, geriatric oncology, decisionmaking

Authol

Abstract Background

Radiotherapy omission after lumpectomy is a reasonable option for many older women with favorable prognosis breast cancer. We sought to evaluate patient perspectives regarding decision-making about radiotherapy (RT).

Methods

Women age 65-79 with stage I and II breast cancer reported to the Georgia and Los Angeles County SEER registries were surveyed (response rate=70%) regarding radiotherapy decisions, the rationale for omitting RT, decision-making values, and understanding of recurrence risk. We also surveyed their corresponding surgeons (response rate=77%). We evaluated patient characteristics associated with omission of RT using multilevel, multivariable logistic regression, accounting for patient clustering within surgeons.

Results

Of 999 patients, 135 omitted RT (14%). Older age, lower grade, and estrogen receptor-positive disease were each strongly associated with omission of RT in multivariable analyses, whereas number of comorbidities was not. Non-English speakers were more likely to omit RT (adjusted OR 5.9, 95% Cl 1.4-24.5).

The most commonly reported reasons for RT omission were that a physician advised the patient it was not needed (54% of patients who omitted RT) and patient choice (41%). Local recurrence

risk was overestimated by all patients, by about 2-fold among those who omitted radiation and 8-fold among those who received radiotherapy. Distant disease recurrence risk was overestimated 3-fold on average.

Conclusions

To some extent, decisions about radiotherapy omission are appropriately influenced by age, grade, and estrogen receptor status, but do not appear to be optimally tailored according to competing comorbidities. Many women who are candidates for radiotherapy omission overestimate their risk of recurrence.

Condensed Abstract: (2 concise sentences)

Radiotherapy omission among older women with early stage breast cancer was appropriately associated with age, grade, and estrogen receptor status, but did not appear to be tailored according to comorbid disease. Despite their favorable prognosis, many older women with early stage breast cancer markedly overestimate the risk of local and distant recurrence.

Autho

Introduction

There is growing concern about overtreatment in older women with early stage breast cancer because they are often more likely to die of competing comorbidities than breast cance.¹ Two trials (CALGB 9343 and PRIME II) have shown that among older women with stage I, estrogen receptor (ER)-positive invasive breast cancer that is treated with breast conserving surgery and endocrine therapy, adjuvant radiotherapy significantly reduces the incidence of local recurrence, but without an apparent influence on the rate of metastasis or breast cancer mortality.^{2, 3} Guidelines now consider omission of RT after BCS as an acceptable treatment option for women age ≥70 with stage T1, clinically node negative, ER-positive breast cancer who receive endocrine therapy.⁴

Some have argued that all older women with characteristics similar to the eligibility requirements for CALGB 9343 and PRIME II should not receive radiotherapy, whether infirm or fit.⁵ Others have advocated for a more individualized approach to decisions about RT that accounts for tumor characteristics, comorbidity, and patient preferences.³ The lack of consensus regarding the treatment approach in this scenario is evident in several practice patterns studies that revealed only a modest decline in RT utilization after publication of CALGB 9343 results.⁶⁻¹⁰ Our previous work evaluating clinician views on radiotherapy omission in this context found that many clinicians overestimate the benefits associated with radiotherapy and continue to consider RT omission to be substandard therapy.¹¹The frequency with which older patients are offered treatment without RT is uncertain, and little is known about their understanding of the risks and benefits of this treatment approach.

In this setting of evolving views on the treatment paradigm for older women with favorable prognosis breast cancer, we sought to evaluate patients' perspectives on the decision about radiotherapy omission as part of a survey that included a sizable sample of older women recently diagnosed with early stage breast cancer, as identified by the population-based Georgia and Los Angeles SEER registries. To our knowledge, this is the first study to evaluate patient views on radiotherapy omission. Our objectives were 1) to evaluate patient characteristics associated with radiotherapy omission; 2) explore patients' rationale for not receiving radiotherapy; and 3) assess patients' understanding of recurrence risk.

Methods

Patient Sample and Data Collection

The Individualized Cancer Care (iCanCare) Study is a large survey study of women with earlystage breast cancer between age 20-79 years who were reported to the population-based Surveillance, Epidemiology and End Results (SEER) registries of Los Angeles County, California and Georgia. Racial minorities were oversampled. Patients with tumors larger than 5cm or stage III to IV disease were excluded. From the iCanCare study, we selected women age ≥65 for the present analysis.

Between July 2013 and August 2015, we identified 7,303 women who were confirmed to be eligible for the study. Surveys were completed a median of 6.8 months (SD 3.2) after diagnosis, with a response rate of 69.6% (n = 5080). The analytic sample (n=999) for the present study

consisted of patients age 65-79 with unilateral invasive breast cancer treated with breast conserving surgery (online supplementary figure 1). Within this sample, 74% of patients had stage I disease and 23% stage II (table 1). Given that we observed a non-negligible rate of radiotherapy omission in stage II patients (12%), we also included stage II patients in multivariable models of radiotherapy omission.

Surveys were mailed with a \$20 cash incentive; a modified Dillman method was used to improve the response rate.¹² Materials were mailed in English; Spanish-translated materials were added for women with surnames that suggested Hispanic ethnicity.¹³ Each SEER registry provided SEER data that were stripped of identifiers and merged to survey data. This study was approved by the University of Michigan Institutional Review Board, the University of Southern California, Emory University, and the public health departments of Georgia and California.

Measures

We developed the questionnaire iteratively with input from survey design experts and cognitive interviews with patients and clinicians to assess content validity, as described previously.¹⁴

The definitive surgical procedure was determined by asking patients to indicate the surgery that was performed after biopsy, and whether additional surgeries were performed. As the primary outcome measure, radiotherapy receipt was determined by asking patients, "Did you or are you planning to have radiation therapy to treat your breast cancer?" as well as whether radiotherapy (RT) was completed, ongoing, or planned. Information on endocrine therapy receipt was available for 62% of the analytic sample (n=619) who completed the survey module on endocrine therapy.

Patient preferences and values were assessed by asking, "When decisions were being made about your treatments, how important was it to you that your treatments..." followed by several prompts (detailed in figure 4), such as, "kept you from worrying about the cancer coming back," each rated on a 5 point Likert-type scale ranging from "not at all important" to "very important." Women who omitted radiotherapy were asked to indicate the reasons for their decision in a "mark all that apply" format. Responses were aggregated into higher (i.e. a lot, quite a bit, or somewhat) and lower (i.e. not at all or a little bit) categories for analysis.

We evaluated patient perceptions of recurrence risk by asking, "After receiving all the planned treatments, what do you think is the chance that your cancer will come back in the breast or the area around it within 10 years?" with instructions to write in a number from 0% to 100%. A similar question was asked about "the chance that your cancer will spread to other parts of your body within 10 years." We asked patients how often they had worried about their cancer coming back within the past month, with responses on a 5-point scale ranging from "almost never" to "almost always," dichotomizing those who reported "sometimes," "often," or "almost always" worrying from those reporting worrying "rarely" or "almost never." We asked how much doctors discussed the chance of cancer recurrence, ranging from "not at all" to "a lot" on a 5-point scale. Patients' decision control preferences were evaluated by asking if they

"preferred to make [their] own decisions," with responses as "quite a bit of the time" or "all of the time" dichotomized from "some of the time," "a little of the time," and "none of the time."

Additional covariates included patient-reported information on comorbidities, race/ethnicity (white, black, Asian, Latina, other), education (no college vs at least some college), income (<\$20, \$20-40, \$40-60, \$60-90, >\$90, in thousands), insurance (private, Medicare, Medicaid, other), marital status (married, divorced/separated, never married, widowed), and travel time to the nearest radiation oncology facility (<15, 15-30, 31-60, >60 minutes). We asked patients to indicate which language they primarily speak.

Surgeon Sample and Data Collection

Patients were asked to identify their surgeons. From the patient analytic sample, 960 women were linked to 311 treating surgeons, of whom 240 completed a surgeon-specific survey (77%). A mean of 3 patients (IQR 1-4) were linked to each surgeon. Surgeons were asked about their annual breast cancer patient volume, whether the practice included residents and fellows, and number of years in practice. Surgeons were also asked, "How involved are you in the selection of adjuvant radiation therapy approach in your post-lumpectomy patients?" with answers ranging from "not at all involved" to "very involved" on a 5-point scale.

Statistical Analysis. We first calculated the proportion of women omitting radiotherapy overall and by all demographic and treatment factors. Bivariate associations with radiotherapy omission were evaluated using the Rao-Scott χ^2 test. Multivariable, multilevel logistic

regression was used to explore the adjusted associations with radiotherapy omission, with patients as the primary units of observation and the surgeon identifiers as the secondary units (i.e. patients clustered within surgeon) ¹⁵. Models were constructed beginning with patient-level covariates, incorporating surgeon clustering, and finally adding surgeon-level covariates. Area under the receiver-operator curve (AUC) was reported to measure the model's discriminatory ability. All statistical analyses incorporated weights to account for the differential probability of sample selection and survey nonresponse. Additionally, though survey and SEER item nonresponse was low (<5%) for most covariates, we multiply imputed missing items using sequential multiple imputation techniques^{14, 16} to prevent potential bias when using complete-case methods in the presence of missing data. P-values 5% or less were considered significant throughout. All analyses were conducted using the SAS system version 9.4 (Cary, NC, USA).

Results

Radiotherapy Receipt

Table 1 and online supplementary table 1 show the distribution of patient and surgeon characteristics. Overall, 14.4% of women in this sample of older women omitted radiotherapy after breast conserving surgery, with 15.7% omission in the subset of patients with ER+, Stage I disease. Among those who received radiotherapy, 48.1% received conventionally fractionated whole breast RT, 26.6% received hypofractionated whole breast RT, 11% received accelerated partial breast RT, 2.2% reported "other" or the duration was not specified, and 12.1% were

scheduled to receive RT but had not yet received it at the time of survey. On bivariate analysis, age, grade, ER status, SEER region, and income were associated with RT omission. Figure 1 shows the results of a multilevel logistic regression model that includes patient-level variables, SEER site, and surgeon identity. Older patient age, lower grade, and ER-positive disease were each strongly correlated with RT omission. Age 75-79 had a dominant effect, with an odds ratio of 14.4 (95% CI 5.6-37.1) when compared to age 65-69. The odds of non-English speakers omitting RT were greater when compared to English speakers (OR 5.9, 95% CI 1.4-24.5). It is noteworthy that patient comorbidities were not associated with RT omission on either bivariable or multivariable analysis (OR 1.3 for ≥2 vs 0 comorbidities, 95% CI: 0.6-2.9). Surgeon variables were not significantly associated with radiotherapy omission and were therefore not retained in the final model.

The multilevel model predicted RT omission well, with an AUC of 0.83 (95% CI 0.79-0.87). When analyzing clustering according to the surgeon identifier, the odds of a patient omitting radiotherapy would be predicted to increase approximately two-fold (OR 1.83, 95% CI 0.87-3.87) if she were to see a surgeon with a practice approach one standard deviation above the RT omission rate of an average surgeon (while adjusting for other model covariates). However, this trend for surgeon influence was not statistically significant. In a model restricted to the subgroup of patients with information on hormonal therapy, use of endocrine therapy was not significantly associated with radiotherapy omission, although there appeared to be a trend for women who omit radiotherapy to also omit endocrine therapy (OR 2.22, 95% CI 0.87-5.65; data not shown). In a model limited to patients with ER+, stage I disease, we again observed that

age, grade, and non-English speakers were significantly correlated with radiotherapy omission, without significant association with comorbidities, similar to the model derived from the larger analytic sample.

Risk Perception and Communication

In the subset of patients with ER+, Stage I disease, 33.1% of women overestimated their risk of local recurrence after all treatments were received as being >10% at 10 years. Among those who omitted RT, when asked to approximate their risk of local recurrence at 10 years, the mean estimate was 19% at 10 years (compared to the CALGB finding of 10%), and among women who received RT, the mean estimate was 17% (in contrast to CALGB 9343 finding of 2%; figure 2).² The risk of distant disease recurrence risk was similarly overestimated, with 46% of women approximating their risk of distant recurrence as being >5% at 10 years. The mean estimate of 10-year distant recurrence risk was 16.0% (compared to the CALGB finding of 5% both among those who received and omitted RT).² In this group of older women with favorable prognosis, approximately a quarter (26.9%) reported that within the last month, they had "sometimes," "often," or "almost always" worried about their cancer coming back, without significant differences for women who received or omitted RT.

Regarding communication with providers, 46.2% of patients in the overall sample reported that their physicians used numeric estimates to describe the risk of the cancer coming back. Approximately one-third (37.9%) reported that their doctors discussed the chance of the cancer coming back "not at all" or "a little bit." Although the majority of women (70.0%) reported that

they preferred that their doctors tell them what to do for breast cancer treatment, women who omitted radiotherapy were more likely to report that they preferred to make their own decisions about breast cancer treatments than women who received RT (45.8% vs 35.7%,

p=0.03).

Patient Preferences and Values

Among women who omitted radiotherapy, the most commonly reported reasons were that a physician told the patient it was not needed (53.8% of patients who omitted RT) and that the decision was left to the patient and she chose to omit RT (40.9%, figure 3). Concerns about placing an excessive burden on family and absence of discussion with a doctor about RT were uncommon reasons for omitting RT (≤5%). Although 11.8% of patients reported "quite a bit" or "a lot" of worry about current or future financial problems as a result of breast cancer and treatments, <1% of women who omitted radiotherapy reported that cost motivated their treatment decision.

When asked about considerations that were important in their decision-making, the most commonly reported priorities were that the treatment kept them from worrying about the cancer coming back (74.0%), had a low possibility of complications (73.9%), and allowed them to continue caring for their home and family (73.6%, figure 4). Women who omitted radiotherapy more commonly endorsed the importance of avoiding exposure to radiation (69% vs 37%, p<0.001) and the need for fewer trips for treatment visits (49.2% vs 37.2%, p=0.008).

Discussion

In this large, contemporary survey of older women with early stage breast cancer, we observed that to a substantial extent, decisions about radiotherapy omission appear to be appropriately tailored based on older age, ER-positive disease, and lower grade tumor. However, the higher rate of RT omission in non-English speakers and the lack of association with comorbidity observed here are concerning. Incorporation of age and pathology findings into the decision to omit RT may be viewed as a starting point, but there remains a great need to further consider comorbidity status and remaining life expectancy to ensure that decisions about radiotherapy are appropriately individualized.¹⁷

We found that despite having an excellent prognosis, a sizeable proportion of older women with Stage I, ER+ breast cancer overestimate their risk of local recurrence, with an average twofold overestimation in women who omitted RT and 8-fold overestimation in women who received RT. Nearly half of women perceived that their risk of distant recurrence was higher than has been reported in clinical trials, with an average 3-fold overestimation. This unrealistically pessimistic view of recurrence risk is reflected in the report from a quarter of women that they had frequently worried about cancer recurrence within the preceding month. Our observations are consistent with prior reports that notwithstanding a favorable prognosis, a large proportion of the most favorable subgroup in our sample of older women felt they were likely to develop a local or distant recurrence and die from breast cancer, resulting in psychological distress, frequent worry, and lower quality of life.^{18, 19} Overestimation of recurrence risk may lead to a multiplicative overestimation of risk reduction from

interventions,²⁰ resulting in overly generous attribution of benefits obtained from treatment. This might underlie the correlation that has been observed between worry about recurrence and receipt of radiotherapy in prior research.^{21, 22} It is notable that one of the highest priorities that influenced decision-making for women in our study was that the treatment minimize the worry about cancer recurrence. Although radiotherapy undoubtedly does reduce the risk of local recurrence,^{2, 3} our results indicate a need to more clearly communicate the favorable prognosis in this group, and to more directly address worry about recurrence and ensure that decisions are optimally informed.

The effects of patient overestimation of recurrence risk may well relate to physician overestimation that has been demonstrated in other work. In a nationwide survey, 19% of radiation oncologists and 32% of surgeons overestimated the 10-year risk of local recurrence.¹¹ The reluctance of many surgeons and radiation oncologists to consider radiotherapy omission to be a reasonable option in select older women is particularly problematic given the findings of the current study demonstrating that the most common reason given by women for the decision to omit radiotherapy was advice from a doctor that radiotherapy was not needed. Furthermore, most women (70%) preferred that their doctors tell them what to do regarding their breast cancer treatment. Therefore, physicians' attitudes and approaches to communication may be particularly important to ensure that patients do indeed consider all options and their risks and benefits. Many potential mechanisms have been considered as possible drivers of physicians' poor communication practices in this setting, including lack of up-to-date knowledge of clinical trial results,²³ heuristics like risk aversion and anticipatory regret

that may motivate physicians and patients alike to embrace overly aggressive treatments,²⁴ lack of training in effective risk communication skills,²⁵ and financial incentives that reimburse the delivery of care rather than its omission.⁷ Our data suggest a compelling need to evaluate the relative roles of these underlying drivers further in order to develop appropriately targeted interventions that encourage clinicians to improve communication in this regard. We find it striking that one-third of women reported minimal discussions with their providers about the risk of recurrence, which is absolutely essential for a patient to understand the relative impact of interventions like radiotherapy.

Our data suggest that surgeons, who are the first breast cancer clinicians to outline a plan of care, may play an important role in decisions regarding radiotherapy omission. Although we did not detect a statistically significant impact of the surgeon on the likelihood of radiotherapy omission, this may be due to the sample size and distribution of patients across surgeons within our sample. We did, however, observe a notable trend, and others have shown that among women with short life expectancy, the probability of receiving RT varies substantially across primary surgeons.²⁶

We also found that non-English speakers were significantly more likely to omit radiotherapy, even after adjustment for race, income, employment and education. This finding may reflect barriers to high quality decision-making in a vulnerable population. Numerous reports describe non-English speakers as a vulnerable population, particularly Latinas with low acculturation.²⁷⁻³⁰ Latina women who are less acculturated have previously been found to have greater desire for

information, lower satisfaction with breast cancer decision-making,³⁰ and perceived powerlessness in medical encounters,³¹ highlighting a need for greater attention to support these patients and identify potential barriers.³² Although disparities are often viewed in the context of undertreatment of an aggressive cancer, with vulnerability related to known risk factors such as lower education or minority race, it is interesting to note that vulnerability to overtreatment may be an entirely distinct concept that primarily affects classically privileged populations, as has been observed with trends in contralateral prophylactic mastectomy.^{33, 34} The association between language barrier and RT omission is worthy of further exploration in future studies.

We observed a trend for patients who omit radiotherapy to also omit endocrine therapy. This is a particularly concerning finding that merits further evaluation, as receipt of endocrine therapy is known to have a substantial impact in reducing local recurrence³⁵ and is believed to be a key factor in leading to the acceptable rates of local failure observed in trials like CALGB 9343 as compared to historical studies where endocrine therapy was not required.^{36, 37} Endocrine therapy non-adherence and discontinuation are known to be an issue for nearly half of women with breast cancer in general,³⁸ and if women who omit radiotherapy are even more likely to omit endocrine therapy, rates of recurrence may be higher than expected.

Aspects of the study merit comment. Strengths include a contemporary, diverse, populationbased sample with a high response rate and specific measures of patients' clinical decision making. Multiple imputation and weighting were used to account for potential bias related to

missing data, and to ensure that the results were representative of the overall population. Limitations include data obtained from 2 large SEER regions (Georgia and Los Angeles County), which might not reflect the entire US population. The number of patients who omitted radiotherapy is small. Patient responses are necessarily retrospective and may be subject to recall bias. Finally, our study evaluated patients' views of radiotherapy omission, but did not explore views about omitting endocrine therapy rather than radiotherapy.³⁹ Nonetheless, our study offers a novel and clinically relevant view of decision-making in older women with favorable prognosis breast cancer.

In conclusion, our findings indicate several targets for interventions to improve the quality of older women's decision-making in the context of radiotherapy after lumpectomy. First, although decisions about radiotherapy omission are influenced by some clinical factors, interventions are necessary to ensure that decisions reflect not only considerations of age and tumor characteristics but also patients' health status and remaining life expectancy. Second, communication must improve, as patients cannot share in the making of preference-concordant decisions when they are not optimally informed about key facts such as recurrence risk and report that their providers had little discussion with them regarding this. Ultimately, we believe that a combination of physician-facing and patient-facing interventions are necessary, as it appears that both patients and physicians play important roles in the predominant intervention bias that has resulted in overtreatment of many older women with early stage breast cancer.⁷ Our results demonstrate that most older women with breast cancer care about avoiding complications and about avoiding worry about recurrence. Therefore, decision aids

that present risk information in understandable formats, such as pictographs,⁴⁰ constitute particularly promising avenues for the improvement of decision quality in practice. Clear information and communication is critical, both for the subset of older patients with favorable risk disease in whom radiotherapy omission is a reasonable and guideline-concordant option if it accords with individual preferences, and also for the subset with more aggressive or advanced tumors, for whom radiotherapy remains a fundamental component of cure.

Author

References

1. Walter LC, Schonberg MA. Screening mammography in older women: a review. Jama 2014;311(13): 1336-47.

2. Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 2013;31(19): 2382-7.

3. Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol 2015;16(3): 266-73.

 4. National Comprehensive Cancer Network. Breast Cancer. Available from URL: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf [accessed December 12, 2017.

5. Hughes KS, Schnaper LA. Can older women with early breast cancer avoid radiation? Lancet Oncol 2015;16(3): 235-7.

6. McCormick B, Ottesen RA, Hughes ME, et al. Impact of guideline changes on use or omission of radiation in the elderly with early breast cancer: practice patterns at National

7. Soulos PR, Yu JB, Roberts KB, et al. Assessing the impact of a cooperative group trial on breast cancer care in the medicare population. J Clin Oncol 2012;30(14): 1601-7.

Comprehensive Cancer Network institutions. J Am Coll Surg 2014;219(4): 796-802.

8. Shirvani SM, Jiang J, Likhacheva A, et al. Trends in Local Therapy Utilization and Cost for Early-Stage Breast Cancer in Older Women: Implications for Payment and Policy Reform. Int J Radiat Oncol Biol Phys 2016;95(2): 605-16. 9. Shen X, Anne PR, Keith SW, et al. Radiation therapy use and outcomes among older women with ER-positive and ER-negative stage I breast cancer. Am J Clin Oncol 2014;37(3): 241-7.
 10. Rhieu BH, Rajagopalan MS, Sukumvanich P, et al. Patterns of care for omission of radiation therapy for elderly women with early-stage breast cancer receiving hormonal therapy. Pract

Radiat Oncol 2015;5(4): e267-73.

11. Shumway DA, Griffith KA, Sabel MS, et al. Surgeon and Radiation Oncologist Views on Omission of Adjuvant Radiotherapy for Older Women with Early-Stage Breast Cancer. Ann Surg Oncol 2017.

12. Dillman DA, Smyth JD, Christian LM. Internet, Mail, and Mixed-Mode Surveys: The Tailored Design Method. Wiley Publishing, 2008.

13. Hamilton AS, Hofer TP, Hawley ST, et al. Latinas and breast cancer outcomes: populationbased sampling, ethnic identity, and acculturation assessment. Cancer Epidemiol Biomarkers Prev 2009;18(7): 2022-9.

14. Jagsi R, Griffith KA, Kurian AW, et al. Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer. J Clin Oncol 2015;33(14): 1584-91.

15. Anders Skrondal SR-H. Generalized Latent Variable Modeling: Multilevel, Longitudinal, and Structural Equation Models. Chapman & Hall/CRC Interdisciplinary Statistics, 2004.

16. Rubin DB. Multiple Imputation for Nonresponse in Surveys. Hoboken, NY: John Wiley & Sons, 1987.

17. Spratt DE, Jagsi R. Breast and Prostate Cancer: Lessons to Be Shared. Int J Radiat Oncol Biol Phys 2017;98(2): 263-68.

18. Rakovitch E, Franssen E, Kim J, et al. A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 2003;77(3): 285-93.

19. Hawley ST, Janz NK, Griffith KA, et al. Recurrence risk perception and quality of life following treatment of breast cancer. Breast Cancer Res Treat 2017;161(3): 557-65.

20. Black WC, Nease RF, Jr., Tosteson AN. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst 1995;87(10): 720-31.

21. Tewari A, Chagpar AB. Worry about breast cancer recurrence: a population-based analysis. Am Surg 2014;80(7): 640-5.

22. Simard S, Thewes B, Humphris G, et al. Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. J Cancer Surviv 2013;7(3): 300-22.

23. Shumway DA, Griffith KA, Sabel MS, et al. Surgeon and Radiation Oncologist Views on Omission of Adjuvant Radiotherapy for Older Women with Early-Stage Breast Cancer. Ann Surg Oncol 2017;24(12): 3518-26.

24. Katz SJ, Morrow M. The challenge of individualizing treatments for patients with breast cancer. JAMA 2012;307(13): 1379-80.

25. Zikmund-Fisher BJ, Janz NK, Hawley ST, Griffith KA, Sabolch A, Jagsi R. Communication of Recurrence Risk Estimates to Patients Diagnosed With Breast Cancer. JAMA Oncol 2016.

26. Feinstein AJ, Soulos PR, Long JB, et al. Variation in receipt of radiation therapy after breastconserving surgery: assessing the impact of physicians and geographic regions. Med Care 2013;51(4): 330-8. 27. Janz NK, Mujahid MS, Hawley ST, Hamilton AS, Katz SJ. Racial/ethnic differences in quality of life and fear of recurrence after diagnosis of breast cancer. Journal of Clinical Oncology 2008;26(15_suppl): 9526-26.

28. Janz NK, Mujahid MS, Hawley ST, et al. Racial/ethnic differences in quality of life after diagnosis of breast cancer. J Cancer Surviv 2009;3(4): 212-22.

29. Hawley ST, Janz NK, Hamilton A, et al. Latina patient perspectives about informed treatment decision making for breast cancer. Patient Educ Couns 2008;73(2): 363-70.

30. Alderman AK, Hawley ST, Janz NK, et al. Racial and ethnic disparities in the use of postmastectomy breast reconstruction: results from a population- based study. J Clin Oncol 2009;27(32): 5325-30.

31. Garrett PW, Dickson HG, Whelan AK, Roberto F. What do non-English-speaking patients value in acute care? Cultural competency from the patient's perspective: a qualitative study. Ethn Health 2008;13(5): 479-96.

32. Janz NK, Mujahid MS, Hawley ST, Griggs JJ, Hamilton AS, Katz SJ. Racial/Ethnic Differences in Adequacy of Information and Support for Women with Breast Cancer. Cancer 2008;113(5): 1058-67.

33. Hawley ST, Jagsi R, Morrow M, et al. Social and Clinical Determinants of Contralateral Prophylactic Mastectomy. JAMA Surg 2014;149(6): 582-9.

34. Yao K, Stewart AK, Winchester DJ, Winchester DP. Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998-2007. Ann Surg Oncol 2010;17(10): 2554-62.

35. Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 2002;20(20): 4141-9.

36. Lim M, Bellon JR, Gelman R, et al. A prospective study of conservative surgery without radiation therapy in select patients with Stage I breast cancer. Int J Radiat Oncol Biol Phys 2006;65(4): 1149-54.

37. Holli K, Hietanen P, Saaristo R, Huhtala H, Hakama M, Joensuu H. Radiotherapy after segmental resection of breast cancer with favorable prognostic features: 12-year follow-up results of a randomized trial. J Clin Oncol 2009;27(6): 927-32.

38. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010;28(27): 4120-8.

39. Walker GA, Kaidar-Person O, Kuten A, Morgan DA. Radiotherapy as sole adjuvant treatment for older patients with low-risk breast cancer. Breast 2012;21(5): 629-34.

40. Zikmund-Fisher BJ, Witteman HO, Dickson M, et al. Blocks, ovals, or people? Icon type affects risk perceptions and recall of pictographs. Med Decis Making 2014;34(4): 443-53.

Auth

Figure Legends

Figure 1: Odds ratios from a model estimating radiotherapy omission. Odds ratios from a multilevel logistic regression model estimating radiotherapy omission. The model was adjusted for race, income, education, insurance, marital status, BMI, and SEER site. The odds ratio for the surgeon effect represents the amount by which a patient's odds of radiotherapy omission are multiplied if they see a surgeon associated with a rate of radiotherapy omission that is one standard deviation above the average surgeon.

Figure 2: Patient-reported estimates of 10-year risk of local recurrence in patients aged 65-79 with stage I, estrogen receptor positive invasive breast cancer compared to CALGB 9343 results.

Figure 3. Patient reported reasons for omission of radiotherapy. Responses are not mutually exclusive.

Figure 4. Patient reported considerations that influenced decisions about breast cancer treatment.

Online supplementary figure 1: Flow diagram of development of analytic sample.

Table 1: Patient Characteristics

	No. (N=999)	Weighted %	% Omitting RT*	P [†]
Age				
65-69	410	40.2	5.4	< 0.0001
70-74	337	34.1	16	
75-79	252	25.7	26	
SEER Stage				0.5404
1	749	73.5	14.3	
2	218	23.2	12.2	
Not reported	32	3.2	28.2	
ER status				0.0164
Positive	857	85.5	15.3	
Negative	111	11.5	5.2	
Not reported	31	3.0	20.2	
SEER Grade				0.0029
1	346	34.8	18.1	
2	430	43.4	14.4	
3	187	18.2	6.1	
Not reported	36	3.7	17.8	
Comorbidities				0.2995
0	482	49.5	13.6	
1	315	30.3	12.8	
2+	190	18.9	17.8	
Not reported	12	1.3	21.8	
Receipt of endocrine therapy [‡]				0.2222
Yes	449	71.1	13.6	
No Not an article	170	26.8	17.7	
Not reported Site	15	2.1	18.5	0.0113
	522	49.3	11.2	0.0113
Georgia Los Angeles County	477	50.7	17.2	
Primarily speak language other	477	50.7	17.2	0.1279
than English				0.1275
Yes	896	90.9	13.5	
No	89	7.8	20.4	
Not reported	14	1.3	30.4	
Race				0.3019
White	631	67.5	14.9	
Black	160	13.9	10.3	
Latina	136	11.3	14.9	
Asian	52	5.2	10.9	

Other, unknown, or missing	20	2.1	26.6	
Income				0.0265
<20K	163	15.3	15.3	
20К - <40К	183	17.6	9.6	
40K - <60K	136	13.4	15.5	
60K - <90K	134	14.4	10.4	
90K+	147	16.8	11.4	
Don't know/not reported	236	22.6	21	
Education				0.5094
At least some college	614	63.4	13.8	0.5051
No college	365	34.8	15.4	
Not reported	20	1.8	8.6	
	20	1.0	0.0	0.4025
Type of insurance				0.1035
Medicaid	104	9.9	15.3	
Medicare	641	66.1	14.5	
Private	121	12.2	6	
Other	7	0.6	14.7	
Not reported	126	11.2	20.9	
Marital status				0.5347
Married/partnered	523	53.3	13.5	
Not partnered	457	44.8	15	
Not reported	19	1.9	20.5	
BMI				0.1281
Underweight (<18.5)	8	0.7	33.5	
Normal weight (18.5-25)	262	27.8	17.4	
Overweight (>25-30)	323	32.7	12.5	
Obese >30	371	35.7	12.7	
Not reported	35	3.2	18.4	
Bra cup size				0.5723
A/B	289	29.0	15.9	010720
c	322	32.1	14.7	
D	197	19.7	13.3	
DD+	156	15.8	11	
Not reported	35	3.4	17.1	
Distance to nearest radiation				0.5430
oncology clinic [‡]				
≤30 minutes	350		11.3	

>30 minutes	126	11.3	
Not reported	34	54.8	

*Percent omitting RT calculated within the weighted sample

[†]*P* values for differences in the proportion of RT omission; the 'not reported' category (if present) was excluded from the calculation.

[‡]Not all patients were asked to provide this information due to differences in survey versions

anusc Auth




Figure 1: Odds ratios from a model estimating radiotherapy omission. Odds ratios from a multilevel logistic regression model estimating radiotherapy omission. The model was adjusted for race, income, education, insurance, marital status, BMI, and SEER site. The odds ratio for the surgeon effect represents the amount by which a patient's odds of radiotherapy omission are multiplied if they see a surgeon associated with a rate of radiotherapy omission that is one standard deviation above the average surgeon.

215x166mm (300 x 300 DPI)

Autho




Figure 2: Patient-reported estimates of 10-year risk of local recurrence in patients aged 65-79 with stage I, estrogen receptor positive invasive breast cancer compared to CALGB 9343 results.

96x82mm (300 x 300 DPI)

Autho




Figure 3. Patient reported reasons for omission of radiotherapy. Responses are not mutually exclusive.

Author Má

106x59mm (300 x 300 DPI)




Figure 4. Patient reported considerations that influenced decisions about breast cancer treatment.


141x109mm (300 x 300 DPI)

Author

No.*	Weighted
(N = 240)	%
46	19.2
71	29.6
118	49.2
5	2.1
120	50.0
120	50.0
67	27.9
169	70.4
4	1.7
142	59.2
88	36.7
10	4.1
93	38.8
46	19.2
94	39.2
7	2.9
nked to a patient in ta	ble 1 and
	(N = 240) 46 71 118 5 120 120 67 169 4 142 88 10 93 46 94

Online supplementary table 1: Physician Characteristics

Authd



254x190mm (96 x 96 DPI)

Author

A12. Please tell us whether you have ever been <u>told by a doctor</u> that you had any of the following health conditions:


Yes	No	
0	0	a. Chronic bronchitis or emphysema
0	0	b. Heart disease, such as coronary artery disease or congestive heart failure
0	0	c. Diabetes
0	0	d. Blood clots in the legs or the lung
0	0	e. Connective tissue disease, such as lupus or scleroderma
0	0	f. Stroke
0	0	g. Depression
0	0	h) High cholesterol
0	0	i) High blood pressure or hypertension
Att N N S N		

C1. Before your surgery, did you consult with any of these providers about your treatment decisions?

-	Yes	No							
	\circ	\bigcirc	a) Radiation oncologist (a doctor who specializes in radiation treatment)						
	0	b) Medical oncologist (a doctor who specializes in chemotherapy)							
	0	0	c) Plastic surgeon (a doctor who performs breast reconstruction)						
	0	0	 d) Primary care provider (a doctor, physician assistant, or nurse practitioner who sees you for common problems or standard checkups) 						
	0	0	 e) Genetic counselor (someone who reviews your family history and explains the purpose and results of genetic tests) f) Navigator (often a nurse, someone who helps you with your treatment schedule, test results, or who gives you and your family information about breast cancer) 						
_	0	0							
<u>Su</u>	Surgery								
C2	. Wha	at was the <u>fir</u>	<u>st</u> surgery that you	had to remove	your breast can	cer <u>after</u> the biops	y test?		
	 I did not have any surgery after the biopsy					Please go to C3 at the top of the next page			
	0				, L				
		I had a <u>lum</u>	<u>pectomy</u> (removal	of the cancer an	d some surroun	ding tissue)			
		→ a	. Did you have a <u>s</u>	econd lumpecto	<u>my</u> to remove m	ore breast tissue f	rom the <u>same brea</u>	<u>st</u> ?	
	○ Yes – I had another lumpectomy to remove more breast tissue from the same breast								
			No – I only had one lumpectomy						
		b	b. Did you have a mastectomy later, on the same breast?						
			Yes – I had a mastectomy <u>after</u> my lumpectomy						
			○ No – I did not have a mastectomy						
		c	c. <u>How strongly</u> did your doctor recommend that you have a mastectomy after your initial lumpectomy?						
			0	\bigcirc	0	0	0		
			Very strongly	Strongly	Moderately	Weakly	Not at all		
	d. How strongly did you request to have a mastectomy after your initial lumpectomy?								
			\bigcirc	0	0	\bigcirc	0		
			Very strongly	Strongly	Moderately	Weakly	Not at all		
			Please contir	nue to C3 on the	e next page				

- C3. What kind of mastectomy did you have?
 - I did not have a mastectomy
 - O Mastectomy only no reconstruction
 - Mastectomy with reconstruction and I kept my own nipple, called a nipple sparing or nipple saving mastectomy
 - O Mastectomy with reconstruction and my original nipple was removed
- C4. What type of breast reconstruction did you have?
 - I have not had any breast reconstruction surgery
 - O A DIEP flap, TRAM flap, or latissimus dorsi flap (uses your own tissue from the abdomen or back)
 - An implant (silicone or saline)
 - O Other (please explain): _____

C5. Did you have a mastectomy on both breasts?



C6. How important were the following factors in your decision to have a mastectomy on **both breasts**?


	Not at all important	A little important	Somewhat important	Quite important	Very important
a. My age	0	0	0	0	0
b. Having a family history of breast cancer	\bigcirc	0	0	0	0
c. Wanting both breasts to match after reconstruction	0	0	0	0	0
Please continue to C7 on the next page					

Radiation Therapy

Please answer the follo	1								
C8. At the time of your breast cancer diagnosis, how much time did it or would it have taken you to get from your home to the nearest radiation treatment facility?									
O Less than 15 r	ninutes O 31 to 60 minu	tes	I don't know						
15 to 30 minute	es O More than 60	minutes	0						
C9. Did any doctor tell you	u that radiation treatment								
		Yes	<u> </u>	Don't remember					
a. Usually involves daily	trips to an outpatient facility	0	0	0					
b. Can be completed in 3	-4 weeks or less	0	0	0					
C14. <u>Did you</u> or <u>are you c</u>	<u>joing to</u> have radiation therapy t	o treat your	breast cancer?						
Yes – I am finished	Yes – I am still having) Ves Lolan	to have radiation	No					
with radiation therap			naven't started yet						
			Plea	se go to C14a					
	C14a. Why didn't you, or do Please mark <u>ALL</u> th	• •	to have radiation there	apy?					
Please go to C15 below	\bigcirc My doctor(s) did		it with me						
	\bigcirc My doctor(s) and								
			and I chose not to						
			ects or complications						
	\sim I was worried at								
	0		n of a burden on me or	- my family					
	\bigcirc								
	Please go to C18 or	n the next p	age						
\downarrow	5								

This article is protected by copyright. All rights reserved.

C15. How many total weeks of radiation treatments are planned?



Hormonal Therapy

C20. Hormonal therapy helps block estrogen from getting to cancer cells that may remain in the body. Hormonal therapy is sometimes called "anti-estrogen therapy" or "endocrine therapy." Examples include **tamoxifen**, **anastrozole** or Arimidex, **letrozole** or Femara, and **exemestane** or Aromasin.

Have you or are you going to be taking any of these medications? Please mark ONE.

- Yes, I currently take one of these medications
- O Yes, I plan to take one of these medications in the future but haven't started yet
- Yes, I took one of these medications before but no longer take it
- No, I am not taking any of these medications right now and I am unsure whether or not I should start
- O No, I have no plans to take any of these medications

Section D: Decision Making

D1. In general, please tell us how often you have these thoughts and feelings when you make decisions.

	Never	Rarely	Sometimes	Often	Always
a. I worry about making a bad decision	0	0	0	0	0
b. I struggle to decide what the right decision is	0	0	0	0	0
c. I get angry at myself when I have made a bad decision	0	0	0	0	0
d. I worry a lot about the outcomes of my decisions	0	0	0	0	0

D2. When making decisions about how to treat my breast cancer...

	Not at all	A little	Somewhat	Quite a bit	A lot
a. I weighed the pros and cons of all the treatment options	0	0	0	0	0
b. I feel like I really thought through all the issues important to the treatment decisions	0	0	0	0	0
 c. I talked with others – family or friends – before making treatment decisions 	0	0	0	0	0
d. I talked with other breast cancer patients before making treatment decisions	0	0	0	0	0
e. I spent time thinking about all of the treatment options	0	0	0	0	0

D3. When making decisions about how to treat my breast cancer...

	Not at all	A little bit	Somewhat	Quite a bit	Very much
a. I would like to have had more information	0	0	0	0	0
b. I would like to have participated more	0	0	0	0	0
c. I am satisfied with the amount of time I had	0	0	0	0	0
d. I am satisfied with the amount of involvement I had from family and friends	0	0	0	0	0

D4. When decisions were being made about your treatments, how <u>important</u> was it to you that your treatments...

	Not at all important	A little important	Somewhat important	Quite important	Very important
a. Reduced the need for more surgery	0	0	0	0	0
b. Allowed you to avoid side effects of treatment	0	0	0	0	0
c. Allowed you to avoid exposure to radiation	0	0	\bigcirc	0	0
d. Required fewer trips back and forth for treatment visits	0	0	0	0	0
e. Did not make you feel bad about your body	0	0	0	0	\bigcirc
f. Kept you from worrying about the cancer coming back	0	0	0	0	0
g. Allowed you to feel feminine	0	0	0	\bigcirc	0
h. Were the most extensive possible	0	0	0	0	0
i. Were the least extensive possible	0	0	0	0	\bigcirc
j. Allowed you to keep your original breast	0	0	0	0	0
k. Were what your partner/family wanted you to do		0	0	0	\bigcirc
I. Were what your doctor wanted you to do	0	0	0	0	0
m. Were the same treatments that other women you know have received	0	0	0	0	0
n. Were the newest, most advanced treatments available	0	0	0	0	0
o. Had the shortest recovery time	0	0	0	0	\bigcirc
p. Gave you peace of mind	0	0	0	0	0
 q. Allowed you to avoid having follow-up mammograms 	0	0	0	0	0
r. Did not require you to spend a lot of your own money	0	0	0	0	0
s. Had a lower possibility of complications	0	0	0	\circ	0
t. Allowed you to continue to care for your home and family	0	0	0	0	0
u. Allowed you to continue to work for pay	0	0	0	0	0

D5. At the time that decisions were being made about your treatments, how much do you feel that your preferences were considered?

	your preferences	were considered?						
	0	0	0	0	C)		
	Not at all	Slightly M	loderately	Very muc	h Comp	letely		
	S	ection E: Hov	v You Fee	el Abou	t Your D	ecision	S	
		ou <u>feel</u> about the decis					ment. If yo	ur doctor
did	not offer you the	test or treatment that	is listed, pleas	e mark N/A	for "Not app	licable."		
E1.	Please rate the a	mount of informatio	on you had wh	en the follo	wing decision	is were ma	de:	
			Not enough		Just right		Too much	N/A
0	Whather or not to	have radiation therap		0		0	0	-
с.			Jy U	0	0	0		0
E2.	I received enoug	h information about th	ne following to	pics:				
			Stron	alv	Neither a	aree	, c	trongly
			Agre	•••		•		isagree
d. 1	he risk of my bre	ast cancer coming ba	ck O	C)			
E3.	How <u>satisfied</u> an	e you with the decision		A 1944			T . (.))	1
			Not at all satisfied	A little satisfied	Somewhat satisfied	Quite satisfied	Totally satisfied	N/A
e.	Whether or not to	have radiation therap	ру 🔿	0	0	0	0	0

-

Section H: Communicating with Your Doctors

	None of the time	A little of the time	Some of the time	Quite a bit of the time	All of the time
H1. When it came to getting treatment for breast cancer, I preferred to be told what to do	0	0	0	0	0
H2. When it came to getting treatment for breast cancer, I wanted <u>my doctor</u> to tell me what to do	0	0	0	0	0
H3. I preferred to make my <u>own</u> decisions about my treatments for breast cancer	0	0	0	0	0

Section I: Your Thoughts and Feelings

The questions below are important to help us better understand how women like you feel towards the end of treatment and the beginning of the recovery period. Please answer these questions the best way you can.

I1. For the question below, please write in a number from 0% to 100% where...

0% = you think there is absolutely no chance that your breast cancer will

come back in the breast or the area around it in the next 10 years, and

100% = you think it is absolutely certain that your breast cancer will

come back in the breast or the area around it in the next 10 years

After receiving all the planned treatments, what do you think is the chance that your cancer will come back in the breast or the area around it within 10 years?

_____% (0 to 100)

I2. After receiving all of the planned treatments, do you consider the chance of your cancer coming back <u>in the</u> <u>breast or the area around it</u> to be:

0	0	0	0	0
Very low	Low	Moderate	High	Very high

I3. Next, we would like to ask you for your opinion on the chances of your cancer <u>spreading to other parts of your body</u>. For the question below, please <u>write in a number from 0% to 100%</u> where...

 $\overline{0\%}$ = you think there is absolutely no chance that your breast cancer will spread to other parts of your body in the next 10 years, and

100% = you think it is absolutely certain that your breast cancer will spread to other parts of your body in the next 10 years


After receiving all the planned treatments, what do you think is the chance that your cancer will spread to other parts of your body within 10 years?

____ % (0 to 100)

		I3a. Why did you pick	this number?				
	0					· · · · · · · · · · · · · · · · · · ·	
14.	After receiving all th	e planned treatments,	do you consider the	e chance of you	Ir cancer spre	eading to othe	er
	parts of your body t			,			
	\bigcirc	0	0	0		0	
	Very low	Low	Moderate	High	Ver	y high	
15.	How much did your	doctors discuss with ye	ou the chance of yo	our cancer comi	ng back?		
	0	0	0	С)	0	
	Not at all	A little bit	Somewhat	Quite	e a bit	A lot	
16.	When your doctors	discussed the chance	of your cancer com	ing back, did th	ey use		
	0		0	0		0	
	Only word (For example, "sma	ls Oi Ill chance") (For exar	nly numbers nple, "8% chance")	Both words and number		loctors did no the risk with	
17.	Compared to other breast cancer will c	women with similar bre ome back?	east cancer and tre	atment, how like	ely do you th	ink it is that y	our
	0	0	0	0		0	
	Much less likely	Less likely	About the same	More likely	/ N	luch more like	ely
18.	In the past month,	how often have you w	orried about your c	ancer coming b	back?		
	0	0	0	0		0	
	Almost never	Rarely	Sometimes	Often	Alm	lost always	
19.	During the past m	onth, how often has <u>w</u>		cancer coming	back		
			Almost never	Rarely Some	etimes Ofte	Almost en always	
a	Made you feel upse	et?	0	0 (C C	0	

		currect				
b. Made it difficult for daily activities at h	you to carry out your usu ome or at work?		0	0	0	0
c. Made you feel dista	ant from family and friend	ls? O	0	0	0	0
I10. When you see yo breast cancer co	our cancer doctors for follo ming back?	ow-up care, ho	w often do th	iey ask if y	ou are worrie	d abou
0	0	\bigcirc	(С	0	
Almost never	Rarely	Sometimes	0	ften	Almost a	ways
0	Section	K: Home	and Work	<		
<15. How much do yo and treatments?	u worry about current or f				f your breast	cancer
0	0	0	C	\mathbf{D}	0	
Not at all	A little	Somewhat	Quite	a bit	A lot	
_1. What language do	o you <u>primarily</u> speak? P O Mandarin O	lease mark <u>ON</u> Cantonese	<u>NE</u> . ⊖ Korean			
O Spanish	⊖ Vietnamese ⊖	Japanese	O Other (p	lease expl	ain):	
_2. In general, what la	nguage(s) do you <u>read a</u>	nd speak?				
0	0	0	0		0	
Only English	English better than any other language	Both equally	Another la better that		Only anoth language	
_3. What language do	you usually <u>speak at hor</u>	ne?				
0	0	0	0		0	
Only English	More English than any other language	Both equally	Another la more than		Only anoth language	
L4. In what language o	do you usually <u>think</u> ?					
0	0	\bigcirc	0		0	
Only English	More English than any other language	Both equally	Another la more than		Only anoth language	
_5. What language do	you usually <u>speak with y</u>	our friends?				
0	0	\bigcirc	0		0	
Only English	More English than	Both equally 10	Another la	anguage	Only anoth	ier

	any other language	more than English	language
	Section M: A F	Few More Questions	
M1. Today's date is:	, ,		
WIT. TOday's date is.	month day year		
	month day year		
M2. About how tall are	you?feetinch	nes ormeters	
M3. At the time of you	ur breast cancer diagnosis, a	about how much did you weigh?	
pounds	or kilograms		
M4 Before your breas	st surgery , what was your bra	a cup size?	
) D		
) DD		
M5. In the 12 months	before your diagnosis with	breast cancer , what was your exp	erience with your
menstrual periods	?		
○ I had no menstr	ual periods in the 12 months b	before my breast cancer diagnosis	
I had regular (or diagnosis	⁻ the usual timing of) menstrua	al periods in the 12 months before r	ny breast cancer
○ I had a change i	in the timing of menstrual perio	ods in the 12 months before my bre	east cancer diagnosis
M6. In the 12 months at any time – even	•	liagnosis, did you experience hot f	lashes or night sweats
0	0		
Yes	No		
M7. What is your birth	date?	1	
	month day	year	



- O Don't know
- M14. In what country was your mother born?
 - O Don't know

This article is protected by copyright. All rights reserved.

M15. In what country was your father born?	
O Don't know	
M16. Which of the following best describes your race?	Please mark <u>ALL</u> that apply.
⊖ White	⊖ Chinese
 Black or African-American 	⊖ Filipino
O American Indian or Alaska Native	⊖ Japanese
O Native Hawaiian or other Pacific Islander	⊖ Korean
○ Asian Indian	⊖ Vietnamese
○ Other Asian (please explain):	
○ Other Race (please explain):	

Section N: Your Doctors

- N1. We want to learn from doctors about better ways to communicate with patients and their families about treatment decisions. The information you provide below will help us contact the doctors who treat patients with breast cancer. The doctors may be surveyed about their treatment practices. Importantly, your answers will <u>never be shared</u> with any doctors and your personal information including your name will <u>never be used</u> in any communication.
 - a. **Surgeon** who performed your <u>first</u> lumpectomy or mastectomy:

Doctor's last name:	 First name:	

Name of hospital or clinic:	
City:	

Section A: About You and Your Practice


- A1. At how many hospitals do you see patients?
 - 2 3 or more

A2. Does your primary practice have...

 O_1

	Yes	No
a. Residents and/or fellows	\bigcirc	0
 b. Cancer care navigators for newly-diagnosed breast cancer patients to help them with treatment decision making 	0	0

A3. In the past 12 months, approximately what percentage (%) of your new patients were...



A4. In the past 12 months, how many <u>new</u> patients who were diagnosed with <u>breast cancer</u> have you seen? (Please include patients who came to you for a second opinion.)


O None	○ 11 – 20	○ 51 – 100
○ 1 – 10	○ 21 – 50	O More than 100

A5. In the past 12 months, approximately what percent of your newly diagnosed breast cancer patients did you discuss in a multidisciplinary meeting (e.g., a tumor board) to get input on the treatment plan?

○ 0%	○ 10 – 25%	\bigcirc More than 50%
○ 1 – 9%	○ 26 – 50%	

Section I: Radiation Therapy

13. How involved are you in the selection of adjuvant radiation therapy approach in your post-lumpectomy patients?



Section L: A Few More Questions

L1. How many years have you been in practice since completing your residency or fellowship training?

years	
L2. Please PRINT the name of the location where you practice the most:	
L3. How old are you? years	
L4. What is your gender?	
O O Male Female	
L5. Which of the following best describes your race?	Please mark ALL that apply.
⊖ White	⊖ Chinese
 Black or African-American 	
O American Indian or Alaska Native	
O Native Hawaiian or other Pacific Islander	○ Korean
○ Asian Indian	⊖ Vietnamese
○ Other Asian (please explain):	
Other Race (please explain):	

M3. Which **radiation oncologists** do you interact with <u>the most</u> when you are uncertain about the **management of your newly diagnosed patients with breast cancer?** Please **PRINT** the first and last names of up to 2 radiation oncologist whom you would approach <u>to get advice</u>.

Name	Hospital / Institution / Practice	<u>Do you share</u> patients via a tumor board? Yes No	
		\bigcirc	\bigcirc
		0	0
0			
S CO			
T			
Author			